Stevanato Group S.p.A. (STVN)
| Market Cap | 5.30B -21.0% |
| Revenue (ttm) | 1.40B +7.0% |
| Net Income | 153.78M +0.0% |
| EPS | 0.56 +0.2% |
| Shares Out | 273.13M |
| PE Ratio | 34.66 |
| Forward PE | 25.88 |
| Dividend | $0.06 (0.32%) |
| Ex-Dividend Date | Jun 11, 2026 |
| Volume | 267,097 |
| Open | 19.22 |
| Previous Close | 19.21 |
| Day's Range | 19.22 - 19.82 |
| 52-Week Range | 12.89 - 27.99 |
| Beta | 0.78 |
| Analysts | Buy |
| Price Target | 24.47 (+26.13%) |
| Est. Earnings | Nov 5, 2026 |
About STVN
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injector... [Read more]
Financial Performance
In 2025, Stevanato Group's revenue was 1.19 billion, an increase of 7.45% compared to the previous year's 1.10 billion. Earnings were 139.84 million, an increase of 18.73%.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for STVN stock is "Buy." The 12-month stock price target is $24.47, which is an increase of 26.13% from the latest price.
News
Stevanato Group initiated with a Hold at Deutsche Bank
Deutsche Bank initiated coverage of Stevanato Group (STVN) with a Hold rating and $22 price target The company has an “industry-leading position” in several components of pharmaceutical packaging, the...
Stevanato Group Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Double-digit growth in high-value products and biologics is driving margin expansion, with strong GLP-1 and biosimilar demand supporting long-term prospects. Engineering is refocusing on core strengths, while major U.S. investments and plant ramp-ups are set to boost future capacity and profitability.
Stevanato Group Slides: Investor presentation
Stevanato Group has posted slides in relation to its latest quarterly earnings report, which was published on September 14, 2026.
Stevanato Group initiated with a Neutral at UBS
UBS initiated coverage of Stevanato Group (STVN) with a Neutral rating and EUR 23 price target The firm initiated and resumed 25 life science and diagnostics tools companies. UBS views…
Stevanato Group to Participate in Two Upcoming Investor Conferences
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group Earnings Call Transcript: Q2 2026
Second quarter 2026 saw 8% revenue growth, margin expansion, and strong high-value solutions performance, especially in biologics and GLP-1 therapies. The Balda C. Brewer divestiture and Alina pen approval support a strategic shift toward integrated, premium drug delivery systems.
Stevanato Group Earnings release: Q2 2026
Stevanato Group released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Stevanato Group Slides: Q2 2026
Stevanato Group has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Stevanato Group reports Q2 EPS EUR0.08 vs. EUR0.11 last year
Reports Q2 revenue EUR302.0M vs. EUR280.0M last year. CEO Franco Stevanato commented, “Results were in line with our expectations with 8% topline growth driven by 10% growth at constant currency…
Stevanato Group narrows 2026 adjusted EPS view to EUR0.60-EUR0.62
Narrows 2026 revenue view to EUR1.26B-EUR1.28B from EUR1.26B-EUR1.29B.
Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group’s Alina pen injector platform authorized in Europe
Stevanato Group (STVN) announced that liraglutide-based combination products incorporating Stevanato Group’s proprietary Alina pen injector platform have received marketing authorizations in Europe. T...
Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology ...
Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Stevanato Group (STVN) with a Buy rating and $25 price target The firm believes the shares are pricing in “too much skepticism” around the company’s…
Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management
PIOMBINO DESE, Italy--(BUSINESS WIRE)-- #DiabetesTherapies--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions for the pharmace...
Stevanato Group Transcript: Jefferies Global Healthcare Conference 2026
The company is accelerating its shift to high-value, ready-to-fill products, investing heavily in capacity and innovation to serve the growing biologics and GLP-1 markets. Revenue and margins are rising, with a target of 30% EBITDA in 12-24 months, driven by strong demand for advanced syringes and cartridges.
Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders' Meeting
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) (the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical,...
Stevanato Group Transcript: 46th Annual William Blair Growth Stock Conference
With a 75-year legacy, the company has achieved double-digit growth by focusing on high-value pharmaceutical packaging and drug delivery systems. Major investments in global capacity and R&D support leadership in biologics and GLP-1, with high-value products now nearly half of revenue.
Stevanato Group assumed with an Outperform at Wolfe Research
Wolfe Research assumed coverage of Stevanato Group (STVN) with an Outperform rating and $21 price target The firm stated in a research note on Life Science Tools & Diagnostics that…
Stevanato Group Slides: Investor presentation
Stevanato Group has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Stevanato Group Transcript: Bank of America Global Healthcare Conference 2026
Strong growth in high-value solutions, especially for biologics and GLP-1s, is driving revenue and margin expansion. Major capacity investments in the U.S. and Italy are nearly complete, supporting future growth and improved cash flow. Adjusted EBITDA margin is on track to reach 30% by 2027.
Stevanato Group Earnings Call Transcript: Q1 2026
Q1 2026 saw 10% constant currency revenue growth, led by high-value solutions and strong BDS segment performance, while engineering margins improved despite lower revenue. Guidance for 2026 is maintained, with robust demand for cartridges and biologics, and ongoing investments in capacity expansion.
Stevanato Group Earnings release: Q1 2026
Stevanato Group released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Stevanato Group Slides: Q1 2026
Stevanato Group has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.